
FDA Approves Gilead’s Once-Daily HIV Pill Bixlenvo
The U.S. Food and Drug Administration officially approved Gilead Sciences’ new once-daily oral combination pill, named Bixlenvo, for treating adults with human immunodeficiency virus. Announced on Thursday, the regulatory decision targets virologically suppressed patients managing complex treatment regimens or experiencing resistance to traditional therapies. The medication combines bictegravir and lenacapavir...








